Clinical Trials
As an infrastructure at the German Center for Infection Research (DZIF), the Clinical Trial Unit tracks DZIF's study activities in the “Healex Site Management System (SMS)”. Studies are sorted by indication and are continuously updated.
The study register has recently been expanded to include the category “COVID-19”. For the first time, not only DZIF study activities are presented here: In order to provide a comprehensive overview in the current pandemic situation of planned and already active COVID-19 studies in Germany, the Clinical Trial Unit is cooperating with researchers from various German Centers for Health Research and other networks.
For researchers: If your study is not yet included in our portal, please contact the project management of the Clinical Trial Unit.
- Viral Infections
- COVID-19
- Therapy Studies
- APN01-COVID-19: Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
- CAPSID: A randomized, prospective, open label clinical trial on the use of convalescent plasma compared to best supportive care in patients with severe COVID-19
- COMIHY: Hydroxychloroquine for the treatment of mild COVID-19 disease
- COVID-19-ACE-ID-201: A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19
- COVID-19 Hydroxychloroquine for COVID-19: Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019 – COVID-19
- COVID-19 WA42380: A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA
- CovidVal01:
- COVit:
- GI-HOPE: GM-CSF Inhalation to improve HOst defense and Pulmonary barrier rEstoration
- GS-US-540-5773: Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)
- GS-US-540-5774: A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment
- ITAC Inpatient Treatment with Anti-Coronavirus Immunoglobulin: An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19
- RECOVER: A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease
- RuxoCoFlaM: A Phase-II Clinical Trial for First Line Treatment of Stage II/III Covid-19 Patients to Treat Hyperinflammation
- RUXOCOIL: A single-arm, open-label, phase II study of ruxolitinib in Covid-19 patients at risk of developing acute respiratory distress syndrome
- WHO-SOLIDARITY-GERMANY: An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - WHO-SOLIDARITY-GERMANY
- Impfstudien
- Prophylaxis Studies
- Antibody Studies
- Compassionate Use Programme
- COVID-19 Remdesivir Compassionate Use: Remdesivir compassionate use program
- Diagnostic Studies
- Antigen POC Tests COVID-19: Evaluation of the performance of novel rapid diagnostics for SARS-CoV-2 at point-of-care
- COVID-19 RNA Bluttest: Blood RNA COVID-19 Evaluation Test
- EIKOS: Exploring immunological control of SARS-CoV-2
- Non-interventional Studies, Biobanking, Registries
- Aspergillosis in COVID19 on ICU: Pulmonary Aspergillosis in Critically Ill COVID19 Patients in Intensive Care Unit - a Multinational Explorative Trial
- CoPa:
- Corona und Kognition:
- CORSAAR:
- COVID-19 Case-Cluster-Study-Heinsbergstudie:
- COVID-19 Immungenetik: Immunogenetic Characterization of COVID-19 Disease
- COVID-19 LEOSS Register: Lean European Open Survey on SARS-CoV-2
- COVID-19 Mobile Tests für Köln - Community: COVID-19 Mobile Tests für Köln - Community
- COVID-19 Mobile Tests für Köln - Uniklinik: COVID-19 Mobile Tests for Cologne
- COVID-19_MPI: The Multidimensional Prognostic Index (MPI) for the Prognostic Stratification of Older Inpatients with Covid-19: A Prospective Observational Trial
- CovidDB:
- CoVi-Do: Donor Survey to Study Immunogenetic Characteristics of Covid-19
- Deutsches Mukoviszidose-Register: German Cystic Fibrosis Registry
- EIKOS: Exploring immunological control of SARS-CoV-2
- GPN Register für COVID-19:
- ISI - Improving Diagnosis of Severe Infections in Immunocompromised Patients: Improving Diagnosis of Severe Infections in Immunocompromised Patients (ISI)
- Kidney in COVID-19: Kidney in Coronavirus Disease 2019 Registry
- NAPKON HAP: Analysis of pathophysiology and pathology of coronavirus disease 2019 (COVID-19), including chronic morbidity
- Pa-COVID-19: Phenotyping platform and logitudinal register for COVID-19 patients at Charité
- ProCoV:
- PROTEGO: Evaluation of the course of COVID-19 disease and perceptions among those tested positive – a prospective and retrospective survey based study
- PROVID-CAPSyS:
- PROVID-PROGRESS:
- RespVir Network: The Respiratory Viruses Network
- Telemed500-Covid-19:
- Master Protocols
- COVID-19 Clinical Trials Master Protocol: A Multi-center, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients
- SARS-CoV-2 Best Practice
- FAQ SARS-CoV-2 bei Krebspatienten: Frequently asked questions regarding SARS-CoV2 in cancer patients – recommendations for clinicians caring for patients with malignant diseases
- EU-COVAT-1 Aged: A Multinational, Phase 2, Randomised, Adaptive Protocol to Evaluate Immunogenicity and Reactogenicity of Different COVID‐19 Vaccines Administration in Older Adults (≥75) Already Vaccinated Against SARS‐CoV‐2 (EU‐COVAT‐1 Aged)
- ITAC Inpatient Treatment with Anti-Coronavirus Immunoglobulin: An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19
- PROVID-CAPSyS:
- PROVID-PROGRESS:
- Telemed500-Covid-19:
- Therapy Studies
- MERS-CoV
- Ebola
- Hepatitis
- HIV / AIDS
- Influenza
- Varizella zoster
- COVID-19
- Bacterial Infections
- Infektionen bei Immungeschwächten Patienten
- Invasive Pilzinfektionen
- Gastrointestinale Infektionen